Top-News

Karyopharm Therapeutics Aktie News

Aktie
WKN:  A40YLC ISIN:  US48576U2050 US-Symbol:  KPTI Branche:  Biotechnologie Land:  USA
5,75 $
-0,16 $
-2,71%
4,9383 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
2,72 Mio. €
Streubesitz
54,56%
KGV
-1,11
Index-Zuordnung
-

Karyopharm Therapeutics News

01.12.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.12.25 - PR Newswire
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference PR Newswire
03.11.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
03.11.25 - PR Newswire
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress PR Newswire
27.10.25 - PR Newswire
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 PR Newswire
08.10.25 - PR Newswire
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 ...
01.10.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
10.09.25 - PR Newswire
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis PR Newswire
02.09.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
11.08.25 - PR Newswire
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress PR Newswire
05.08.25 - PR Newswire
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 PR Newswire
01.08.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.07.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
03.06.25 - PR Newswire
Karyopharm to Present at the Jefferies Global Healthcare Conference
Karyopharm to Present at the Jefferies Global Healthcare Conference PR Newswire
02.06.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
19.05.25 - PR Newswire
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference PR Newswire
14.05.25 - PR Newswire
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting PR Newswire
12.05.25 - PR Newswire
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume ...
08.05.25 - PR Newswire
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 PR Newswire
01.05.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Newssuche

Videos

newspaper
18:20 Uhr
Master the Trading!
In diesem Trading-​Webinar haben wir von A bis Z den Aufbau professionellen Tradings thematisiert und ... Mehr »